Advisors Asset Management Inc. lessened its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Rating) by 2.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 61,738 shares of the biopharmaceutical company’s stock after selling 1,552 shares during the quarter. Advisors Asset Management Inc.’s holdings in Amicus Therapeutics were worth $645,000 at the end of the most recent quarter.
Other hedge funds have also recently added to or reduced their stakes in the company. Duality Advisers LP bought a new stake in Amicus Therapeutics in the third quarter valued at $1,927,000. Peregrine Capital Management LLC lifted its stake in Amicus Therapeutics by 4.1% in the third quarter. Peregrine Capital Management LLC now owns 812,361 shares of the biopharmaceutical company’s stock valued at $8,481,000 after buying an additional 31,957 shares during the last quarter. ProShare Advisors LLC lifted its stake in Amicus Therapeutics by 2.3% in the third quarter. ProShare Advisors LLC now owns 53,997 shares of the biopharmaceutical company’s stock valued at $563,000 after buying an additional 1,211 shares during the last quarter. Assetmark Inc. lifted its stake in Amicus Therapeutics by 71.0% in the third quarter. Assetmark Inc. now owns 20,570 shares of the biopharmaceutical company’s stock valued at $215,000 after buying an additional 8,543 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale lifted its stake in Amicus Therapeutics by 122.8% in the second quarter. DekaBank Deutsche Girozentrale now owns 217,700 shares of the biopharmaceutical company’s stock valued at $2,298,000 after buying an additional 120,000 shares during the last quarter.
Insider Activity at Amicus Therapeutics
In related news, CEO Bradley L. Campbell sold 5,485 shares of the business’s stock in a transaction that occurred on Thursday, December 1st. The stock was sold at an average price of $12.20, for a total value of $66,917.00. Following the completion of the sale, the chief executive officer now owns 689,618 shares of the company’s stock, valued at approximately $8,413,339.60. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, CEO Bradley L. Campbell sold 5,485 shares of the business’s stock in a transaction that occurred on Thursday, December 1st. The stock was sold at an average price of $12.20, for a total value of $66,917.00. Following the completion of the sale, the chief executive officer now directly owns 689,618 shares in the company, valued at approximately $8,413,339.60. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Chairman John F. Crowley sold 11,347 shares of the business’s stock in a transaction that occurred on Thursday, December 1st. The stock was sold at an average price of $12.20, for a total value of $138,433.40. Following the completion of the sale, the chairman now owns 801,922 shares of the company’s stock, valued at $9,783,448.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 380,639 shares of company stock valued at $4,769,008. 2.40% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
Amicus Therapeutics Trading Down 1.2 %
NASDAQ:FOLD opened at $12.49 on Wednesday. The company has a debt-to-equity ratio of 2.95, a current ratio of 2.78 and a quick ratio of 2.70. Amicus Therapeutics, Inc. has a fifty-two week low of $5.91 and a fifty-two week high of $13.61. The stock’s 50-day moving average is $12.41 and its two-hundred day moving average is $11.58. The stock has a market cap of $3.51 billion, a PE ratio of -13.58 and a beta of 0.86.
About Amicus Therapeutics
Amicus Therapeutics, Inc operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio.
Featured Stories
- Get a free copy of the StockNews.com research report on Amicus Therapeutics (FOLD)
- LCI Industries Diversification Strategy Pays Off
- Is It Time To Buy The Dip In The Coca-Cola Company
- Ex-Dividend Date vs. Record Date: What’s the Difference?
- How Does the Consumer Price Index Affect the Stock Market?
- Are Denny’s Corporation Investors Due For A Grand Slam?
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-logo.gif&h=45&w=95&zc=2){kind=logo}
